



Breadcrumb

1. [Home](#)

Entity Print

The EBMT Global committee (EGC) was created by the EBMT Board in October 2017 to further extend the scope of stem cell transplantation and cell therapy to as many transplant teams as possible outside Europe to extend further our common knowledge, medical training and research.



Norbert Claude Gorin
GLOBAL COMMITTEE CHAIR
France

Foreword

EBMT has made a considerable effort to help our Chinese colleagues to join and not surprisingly this report will deal very much with our common progress in China.

But the role of the EGC is of course global and we heartily welcome all new members and encourage all members of the EGC to help as much as they can to further increase our scientific knowledge and get benefit for both transplant teams and patients.

The present report is very much oriented to China and the year 2022 has been complicated by COVID. Nonetheless meetings online have never stopped. We hope the next EGC meeting will cover new collaborations with many other countries.

Educational Scientific Meetings

In 2022, three meetings were co-organized by EBMT and Chinese national organisations: two for physicians and one for nurses. Once again the help of the Boxiao foundation including Eva Yu must be acknowledged.

A first EBMT-China inaugural Scientific Forum co-organised by EBMT and the national research centre for translational medicine in Ruijin Hospital, took place in Shanghai on June 24, 2022, under the co-presidency of our colleagues: Saijuan Chen, Xiaojun Huang, Depei Wu, and He Huang. Weili Zhao and Aibin Liang acted as Executive Presidents. The director of the national centre and a representative of the science and technology commission of the Shanghai municipality assisted us. 300 colleagues were connected online.

A second EBMT-China Scientific Forum co-organized by EBMT, the Institute of haematology and Blood diseases of Tianjin, the Chinese academy of medical sciences and the Peking Union College, took place in Tianjin on November 18, 2022, under the co-presidency of Jianxiang Wang, Director of the institute and Erjie Jiang, acting as Executive President. The program was devoted to the treatment of Acute Myeloid Leukemia. 500 participants registered and nearly 20,000 watched the forum online since the Tianjin team made a replay of the forum available. Read the event report [HERE](#).

Nicolaus Kroeger, Anna Sureda and Norbert Claude Gorin chaired these forums.

On the occasion of the 17th National Haematology Academic Conference of the Chinese Medical Association, **the first EBMT- China Nursing Forum** (in-person and online) was successfully held on September 24, 2022 at the National Exhibition and Convention Center (Shanghai) with the support from Yan Xia, Chairwomen of the Chinese Haematological Disease Nursing Branch and Michelle Kenyon, the EBMT Nurses Group President. Read the event report [HERE](#).

Scientific Production

At the time of writing this report, 6 projects have been initiated by EBMT-China. They are listed below:

1. A Chinese national survey of transplant activity in China (around 12,000 transplants per year): Dr CHEN Jia as Principal Investigator (PI): completed
2. A retrospective study of the outcomes post haploidentical transplants comparing first degree versus non first degree donors (oral presentation EBMT 2023): Dr YE Yishan PI: completed
3. A retrospective comparison of autologous versus haploidentical transplants in adult patients with AML in first remission (CR1) with undetectable Minimal Residual Disease (uMRD): Dr CHEN Jia PI (Poster at EBMT 2023): completed
4. A retrospective comparison of autologous versus haplo-identical transplants in adult patients with ALL Philadelphia positive receiving TKI as maintenance therapy: Dr RU Yuhua: in progress
5. A retrospective comparative study of haplo-, MSD and MUD allo-HCTs for AML patients with KMT2A rearrangement: Dr YE Yishan PI (oral presentation at EBMT 2023): patient recruitment still in progress to increase statistical power.
6. Outcome post HSCT of adult patients with AML carrying a TET2 mutation: Dr LI Lin PI: in progress.

The EGC would like to acknowledge the help for these studies of the Acute Leukaemia Working Party and in particular Myriam Labopin, Jacques Emmanuel Galimard, Irma Khevelidze, Mohamed Houhou and Emmanuelle Polge.

The EGC encourages all Chinese teams to propose study projects in association with any of the existing Working Parties. Projects are discussed at the working party meetings and if approved chaired by the proposing investigator considered as the PI.

The EGC wants to remind all EBMT teams that they do have to report ALL CONSECUTIVE DATA ON TRANSPLANTED PATIENTS TO THE REGISTRY TO REMAIN BONA FIDE EBMT TEAM MEMBERS.

Special scientific session


During the 48th EBMT Annual Meeting, the EGC organised a session entitled: “[GLOBAL PERSPECTIVE FOR CELLULAR IMMUNE THERAPY](#)” with 5 speakers including 4 from Asia.

New Members

CIC	Centre Name	City	Principal Investigator
401	First Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	Huang HE
443	Peking University People’s Hospital, Institute of Haematology	Beijing	Xiao-jun HUANG
931	First Affiliated Hospital of Soochow University	Suzhou	Depei WU
939	Beijing Jishuitan Hospital	Beijing	Li BAO
1008	Institute of Hematology, Chinese Academy of Medical Sciences	Tianjin	Erlie JIANG
1012	Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine	Shanghai	Jiong HU
1013	Central South University, Xiangya Hospital	Changsha	Yajing XU
1014	Union Hospital of Tongji Medical College of Huazhong University of Science and Technology	Wuhan	Yu HU
1015	Shenzhen Children's Hospital	Shenzhen	Sixi LIU
1016	The First Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Pengcheng HE
1017	Xinqiao Hospital of Army Medical University	Chongqing	Xi ZHANG
1018	Tongji Hospital Affiliated to Tongji Univerisity	Shanghai	Aibin LIANG

CIC	Centre Name	City	Principal Investigator
1023	First Affiliated Hospital of Sun Yat-sen University	Guangzhou	Juan LI
1024	Lanzhou University Second Hospital	Lanzhou	Liansheng ZHANG
1025	First Affiliated Hospital of Xinjiang Medical University	Urumqi	Ming JIANG
1026	Second Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Aili HE
1027	First Affiliated Hospital of Zhengzhou University	Zhengzhou	Yufeng LIU
1028	920th Hospital of Joint Logistics Support Force	Kunming	Sanbin WANG
1029	Beijing Friendship Hospital, Capital Medical University	Beijing	Zhao WANG
1030	The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	Kang YU
1031	Nanfang Hospital, Southern Medical University	Guangzhou	Qifa LIU
1032	First Affiliated Hospital of Zhejiang Chinese Medical University	Hangzhou	Baodong YE

Membership overview in the last three years



Global Committee Team



Rafael Duarte
MEMBER GLOBAL COMMITTEE
Spain



Huang XiaoJun
MEMBER GLOBAL COMMITTEE
China



He Huang
MEMBER GLOBAL COMMITTEE, DEAN OF THE FIRST AFFILIATED HOSPITAL AND
DIRECTOR OF HEMATOLOGY INSTITUTION ZHEJIANG UNIVERSITY SCHOOL OF
MEDICINE
China

Hu Jiong
MEMBER GLOBAL COMMITTEE
China



Liu Kaiyan

MEMBER GLOBAL COMMITTEE

China



Wu Depei

MEMBER GLOBAL COMMITTEE, PRESIDENT CHINESE SOCIETY OF HEMATOLOGY

China

Shinichiro Okamoto

MEMBER GLOBAL COMMITTEE

Japan



Mahmoud Aljurf

MEMBER GLOBAL COMMITTEE

Saudi Arabia



Ali Bazarbachi

MEMBER GLOBAL COMMITTEE, POST-TRANSPLANT PHARMACOLOGIC MODULATION
SUBCOMMITTEE

Lebanon



Gregorio Jaimovitch
MEMBER GLOBAL COMMITTEE
Argentina
William Hwang
MEMBER GLOBAL COMMITTEE
Singapore

EBMT China Office in Shanghai



Nicolaus Kröger
EBMT PRESIDENT, GENERAL REPRESENTATIVE EBMT SHANGHAI OFFICE
Germany



Wu Depei
MEMBER GLOBAL COMMITTEE PRESIDENT CHINESE SOCIETY OF HEMATOLOGY
China



He Huang

MEMBER GLOBAL COMMITTEE DEAN OF THE FIRST AFFILIATED HOSPITAL AND
DIRECTOR OF HEMATOLOGY INSTITUTION ZHEJIANG UNIVERSITY SCHOOL OF
MEDICINE

China



Jia Chen

EXECUTIVE CHINESE PRINCIPAL INVESTIGATOR

China



Yishan Ye

EXECUTIVE CHINESE PRINCIPAL INVESTIGATOR

China

In 2021, the EGC was renewed for two years. Most members of the first EGC have expressed their wish to remain on board. You can view the list of members below.

If you wish to join our team, please contact us. Note that two sponsors are needed. In case of difficulties to find a sponsor, the EGC suggests for applicants to join any EGC member (especially if there is one in their own country) and/or to request their application to be forwarded for special evaluation to the EGC chair.

We have been informed that, early 2023, the localization of the EBMT-China Office in Shanghai will move to a new place at a different address, with the same general facilities. The EGC is grateful in particular to Mrs Eva Yu for ensuring constant connection, help and support linking EBMT Barcelona and Paris Offices to the EBMT China Office and all present Chinese EBMT new team members.

Latin America

Stem cell transplantation and cell therapy are taking off in Latin America. EGC has designated Latin America as its next recruitment effort to come, with the help of EGC Latin America members.

[Visit the Global Committee Webpage](#)

Print to PDF